REMEGEN
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
REMEGEN
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-01-01
Status:
Active
Contact:
(86) 535-6113513
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
SPF Apache PHP Apache 2.2 Alibaba Alibaba Cloud MailBox Win32 Header Apache Tomcat JK AliDNS
Similar Organizations
MabSpace Biosciences
MabSpace Biosciences is a biotech company focused on discovery & development of innovative antibody based therapeutics for cancer.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Lilly Asia Ventures
Lilly Asia Ventures investment in Private Equity Round - Remegen
Vivo Capital
Vivo Capital investment in Private Equity Round - Remegen
Lake Bleu Capital
Lake Bleu Capital investment in Private Equity Round - Remegen
China Reform Fund Management
China Reform Fund Management investment in Private Equity Round - Remegen
Janchor Partners
Janchor Partners investment in Private Equity Round - Remegen
OrbiMed
OrbiMed investment in Private Equity Round - Remegen
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Private Equity Round - Remegen
Loyal Valley Capital
Loyal Valley Capital investment in Private Equity Round - Remegen
Shenzhen Capital Group
Shenzhen Capital Group investment in Private Equity Round - Remegen
Lapam Capital
Lapam Capital investment in Private Equity Round - Remegen
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-19 | Biocytogen | Remegen investment in Post-IPO Equity - Biocytogen | 49.8 M USD |
More informations about "Remegen"
Remegen Biosciences
RemeGen Biosciences is committed to the discovery and development of innovative and differentiated therapeutics. We strive to create value through delivering medicines for the …See details»
Company — Remegen Biosciences
RemeGen Biosciences focuses on the discovery and development of innovative medicines for the treatment of cancer and autoimmune diseases. We leverage our deep insights into human …See details»
RemeGen Biosciences - Crunchbase Company Profile & Funding
RemeGen Biosciences operates in the biotechnology industry, focusing on the discovery and development of innovative and differentiated therapeutics. The company is committed to …See details»
Remegen - Crunchbase Investor Profile & Investments
RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong …See details»
RemeGen Co., Ltd. (HKG: 9995) Company Profile & Overview
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic …See details»
Remegen Company Profile - Office Locations, Competitors ... - Craft
Remegen is a company that develops biopharmaceutical products. The company focuses on research and development, manufacturing and commercialization of biologics, notably …See details»
Seagen and RemeGen Announce Exclusive Worldwide License and …
Aug 9, 2021 · RemeGen’s main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody …See details»
Remegen - Funding, Financials, Valuation & Investors - Crunchbase
Remegen is a biotech company focused on discovering and developing a new generation of targeted therapies for the treatments of cancer.See details»
RemeGen Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
About RemeGen Co. Ltd. Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical …See details»
O’Melveny Represents RemeGen in its Exclusive Worldwide License ...
HONG KONG—AUGUST 11, 2021—O’Melveny recently represented RemeGen Co., Ltd. in entering into an exclusive worldwide license agreement with Seagen Inc., a global …See details»
LRA Salutes RemeGen on FDA Fast-Track Designation for Potential …
Apr 16, 2020 · The U.S. Food and Drug Administration granted fast-track designation to RC18, a potential lupus treatment in development by a company in China, RemeGen.See details»
World Cancer Day 2024: RemeGen Announces Three Significant …
Feb 2, 2024 · Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical …See details»
RemeGen Reiterates Commitment to Its Battle Against …
Dec 15, 2021 · Founded in 2008, RemeGen (9995.HK) is China's leading biopharmaceutical company committed to providing solutions to the unmet clinical needs of patients suffering …See details»
JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes …
Jan 11, 2024 · After Pfizer closed the Seagen deal in December, word came out that the company put down $53 million in upfront and near-term payments—and up to $1.05 billion in …See details»
HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn
2 days ago · Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from …See details»
Remegen's Innovative New Drug Telitacicept (RC18) Obtains …
Sep 27, 2023 · Telitacicept is an innovative B-cell lymphocyte stimulator/proliferation inducing ligand (BLyS/APRIL) dual-target fusion protein drug independently developed by RemeGen …See details»
RemeGen Co., Ltd. ESG Risk Rating - Sustainalytics
Oct 14, 2024 · RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers …See details»
RemeGen Hopes For Pain Relief From Expanded Drug Uses
Firms such as novel drugs maker RemeGen Co. Ltd. (OTCPK:REGMF) have seen their shares repeatedly hammered, as investors fret about the business impact of the government’s …See details»
Remegen - Contacts, Employees, Board Members, Advisors
Remegen is a biotech company focused on discovering and developing a new generation of targeted therapies for the treatments of cancer.See details»
RC-148 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 10, 2024 · RC-148: a PD-1 modulators, VEGF modulators Drug, Initially developed by RemeGen Co., Ltd.,See details»